Results 71 to 80 of about 7,093,593 (187)

Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market : Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014 [PDF]

, 2015
On September 11, 2014, a workshop entitled 'Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Product Successfully to the Market' was held at the 47th annual meeting of the German Society for Transfusion Medicine and Immunohematology
Hystad, Marit, Beuneu, Claire, Flory, Egbert, Salmikangas, Paula, Celis, Patrick, Doevendans, Pieter A., Ferry, Nicolas, Ferry, Nicholas, Reischl, Ilona, Schüßler-Lenz, Martina   +9 more
core   +1 more source

Extracellular Vesicles: Classification, Biological Functions, Diseases, and Therapeutic Opportunities

MedComm, Volume 7, Issue 10, October 2026.
• EV content maintains cellular homeostasis and is involved in several disease onset and progression. • miRNA export in EVs depends on: RNA‐binding proteins recognizing motif sequences and on epitranscriptomic modifications. • The disclosure of delivery mechanisms is crucial for developing personalized EV‐based therapeutic tools. ABSTRACT Extracellular
Sabrina Garbo, Francesco Marocco, Clemens Zwergel, Marco Tripodi, Cecilia Battistelli   +4 more
wiley   +1 more source

Mesenchymal Stem Cell‐Derived Extracellular Vesicles Ameliorate NaIO3‐Induced Dry AMD by Delivering miR‐486‐3p to Inhibit Lipocalin‐2‐Mediated Ferroptosis

MedComm, Volume 7, Issue 10, October 2026.
Our study reveals a novel mechanism by which MSC‐derived EVs alleviate NaIO3‐induced dry AMD‐like pathology. MSC‐EVs deliver miR‐486‐3p into retinal cells to directly inhibit the ferroptosis‐promoting target gene Lcn2. Concurrently, downregulated Lcn2 restores intracellular Gpx4 expression, thereby suppressing ferroptosis and rescuing retinal ...
Zheng Li, Tujing Zhao, Lin Ye, Runze Li, Huaping Tian, Ruilin Liao, Lulin Huang   +6 more
wiley   +1 more source

Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

, 2023
Objectives Advanced therapy medicinal products (ATMPs) are drugs for human use for the treatment of chronic, degenerative, or life-threatening diseases that are based on genes, tissues, or cells.
Olry-de-Labry-Lima, Antonio, Ponce-Polo, Angela, Pérez-Troncoso, Daniel, Epstein, David, García-Mochón, Leticia, Ortega-Ortega, Marta   +5 more
core   +1 more source

Optimal Hypoxia Mimetic Small Molecules for Enhancing Angiogenic Properties of Stem Cells From Human Exfoliated Deciduous Teeth

International Endodontic Journal, Volume 59, Issue 10, Page 2122-2142, October 2026.
ABSTRACT Aim Hypoxic preconditioning of cells holds promise for regenerative therapies, yet identifying effective and safe methods for clinical application remains challenging. We aimed to determine optimal hypoxia‐mimetic small molecules (SMs) that stabilize hypoxia‐inducible factor‐1α (HIF‐1α) and their dosages for hypoxic preconditioning in stem ...
Hong Wang, Jiawei Liu, Xintao Yang, Mohamad Koohi‐Moghadam, Shuting Gao, Yuanyuan Han, Dineshi Sewvandi Thalakiriyawa, James Kit Hon Tsoi, Yanqi Yang, Waruna Lakmal Dissanayaka   +9 more
wiley   +1 more source

Cryopreservation Methods in Manufacturing of Advanced Therapy Medicinal Products [PDF]

, 2022
This dissertation deals with application of cryopreservation methods in the production and transport of advanced therapy medicinal products (ATMPs), including temporary storage in the Hospital cryostorage facility prior its clinical use. This work kept a
Jandová, Miroslava
core  

Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno‐Free Culture Systems

Advanced Healthcare Materials, Volume 15, Issue 34, 11 September 2026.
Advances in cell sources, bioengineering, and manufacturing are reshaping the design of skin substitutes. This review highlights emerging strategies driving skin tissue engineering and discusses their potential to enable safer, reproducible, and clinically accessible skin substitutes for regenerative medicine.
Gilles Lemaître, Marina Trouillas, Tatiana Vinasco‐Sandoval, Cécile Giordano, Alexandre G. Lellouch, Walid Rachidi, Jean‐Jacques Lataillade, Nicolas O. Fortunel   +7 more
wiley   +1 more source

Advanced therapy medicinal products: regulation and licensing in Great Britain

How to get a marketing authorisation for an Advanced Therapy Medicinal Product (ATMP) so it can be sold and/or supplied in Great Britain. Read the press release from Medicines and Healthcare products Regulatory Agency published on 19 March ...
lsgilbert
core   +1 more source

Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO)

Stem Cell Research & Therapy, 2018
Background Cell therapy with bone marrow (BM)-derived progenitors has emerged as a promising therapeutic for refractory angina (RA) patients. In the present study, we evaluated the safety and preliminary efficacy of transcatheter delivery of autologous ...
Beatrice Bassetti, Corrado Carbucicchio, Valentina Catto, Elisa Gambini, Erica Rurali, Alberto Bestetti, Giuseppe Gaipa, Daniela Belotti, Fabrizio Celeste, Matteo Parma, Stefano Righetti, Lorenza Biava, Maurizio Arosio, Alice Bonomi, Piergiuseppe Agostoni, Paolo Scacciatella, Felice Achilli, Giulio Pompilio   +17 more
doaj   +1 more source

Cell sources of advanced-therapy medicinal products (ATMPs)

, 2018
In Work Package 2, our aim was to answer to the following questions: what 18are the interactions between EU and national legislation and the procurement of human (embryonic, foetal, and adult) stem cells for research, innovation and therapy and what are the effects of the application and implementation of that legislation on human stem cell procurement.
Varju, Márton, Jasper, Bovenberg, Sándor, Judit   +2 more
openaire   +1 more source